valrubicin topical cream / Valderm - LARVOL DELTA

Immunologic Response to a Therapeutic Cancer Vaccine (PANVAC): Initial Results from A Randomized Phase 2 Clinical Trial (AUA 2017) - "...25% of patients also had intravesical chemotherapy prior to enrollment (2 patient had Mitomycin C, 2 patients had Valrubicin)... BCG + PANVAC appears to induce an immunological response that is greater than BCG alone in many patients. The impact of this immunological response on patient outcomes will continue to be assessed as the trial matures."

Clinical • P2 data • Biosimilar • Bladder Cancer • Oncology • Urothelial Cancer

Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study. (PubMed, J Chem Inf Model) - "Several promising known drugs stand out as potential inhibitors of SARS-CoV-2 main protease, including carfilzomib, eravacycline, valrubicin, lopinavir, and elbasvir. I found that one hotspot residue HIS41, is a conserved residue across many viruses including SARS-Cov, SARS-Cov-2, MERS-Cov, and HCV. The findings of this study can facilitate rational drug design targeting the SARS-Cov-2 main protease."

Journal • Hepatitis C Virus • Novel Coronavirus Disease • Oncology

Staphylococcal Exotoxins Induce Interleukin 22 in Human Th22 Cells. (PubMed) - "Increased IL-22 secretion can promptly be induced by staphylococcal exotoxins in skin infiltrating CD4+CD45RO+CD45RA- memory T cells and can potentially amplify chronic skin inflammation in AD in the context of bacterial colonization and infection. This should be investigated further in detail in lesional skin of AD and psoriasis patients."

Journal • Biosimilar • Colorectal Cancer • Dermatitis • Eczema • Hematological Malignancies • Immunology • Inflammation • Oncology • Psoriasis

Salvage therapeutic strategies for bacillus Calmette-Guerin failure. (PubMed, Curr Opin Urol) - "Salvage therapeutic bladder-sparing strategies for BCG failure such as intravesical chemotherapy or chemoradiation should currently only be considered in patients unfit for or refusing surgery. Innovative concepts such as chemohyperthermia, checkpoint inhibitors, targeted therapy or viral gene therapy could lead to major changes in clinical management of BCG failures in the future."

Journal

Current advances in BCG-unresponsive non-muscle invasive bladder cancer. (PubMed, Expert Opin Investig Drugs) - "Although many agents are currently undergoing testing, none have been approved since Valrubicin...Other considerations in this realm include the use of biomarkers in NMIBC to identify patients who will most likely respond to specific interventions. In addition, as systemic agents such as checkpoint inhibitors, are studied further, a multidisciplinary approach may be needed to treat this subset of patients."

Biomarker • IO Biomarker • Journal